OTCPK:ARLZQ - Post by User
Post by
snootchybootchyon Oct 21, 2016 7:50pm
156 Views
Post# 25373238
Concordia
ConcordiaWild volatility in Concordia's share price today as CEO Mark Thompson stepped down. Opened at $5.43 and went up to $7.39 and then closed back down at $5.98. I'm thinking the new CEO will likely look to sell off assets. The new CEO may be willing to sell them at discounted prices since he/she will not be as emotionally invested in these drugs. I noticed Concordia has a few cardiovascular-related drugs on its roster, which may be attractive to Mr. Adams.
I know I mentioned this before on this board but Jonathan Goodman predicted good deals could be had in Q4 2016 or Q1 2017 as over-leveraged drug companies will be seeking to sell assets in order to de-lever. And 15 months or so ago when pharmaceutical stocks were going through the roof, frustrated Knight shareholders thought Mr. Goodman was being overly cautious with his trove of cash but he maintained the valuations of the pharma acquisitions at the time were unsustainable. It's pretty amazing how often his prognostications have turned out to be correct.